CN117257866A - Traditional Chinese medicine composition for treating community-acquired pneumonia and application thereof - Google Patents
Traditional Chinese medicine composition for treating community-acquired pneumonia and application thereof Download PDFInfo
- Publication number
- CN117257866A CN117257866A CN202310415233.7A CN202310415233A CN117257866A CN 117257866 A CN117257866 A CN 117257866A CN 202310415233 A CN202310415233 A CN 202310415233A CN 117257866 A CN117257866 A CN 117257866A
- Authority
- CN
- China
- Prior art keywords
- parts
- raw
- chinese medicine
- traditional chinese
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 35
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 31
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 31
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 31
- 235000011477 liquorice Nutrition 0.000 claims abstract description 31
- 241000218671 Ephedra Species 0.000 claims abstract description 25
- 244000018633 Prunus armeniaca Species 0.000 claims abstract description 23
- 235000009827 Prunus armeniaca Nutrition 0.000 claims abstract description 23
- 240000000249 Morus alba Species 0.000 claims abstract description 22
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 22
- 240000004980 Rheum officinale Species 0.000 claims abstract description 18
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 18
- 241000202726 Bupleurum Species 0.000 claims abstract description 12
- 229910052602 gypsum Inorganic materials 0.000 claims abstract description 11
- 239000010440 gypsum Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 7
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000011505 plaster Substances 0.000 claims description 12
- 239000004575 stone Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 239000008213 purified water Substances 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 16
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 11
- 208000026435 phlegm Diseases 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 238000010926 purge Methods 0.000 abstract description 6
- 210000004185 liver Anatomy 0.000 abstract description 3
- 241000721047 Danaus plexippus Species 0.000 abstract description 2
- 239000002671 adjuvant Substances 0.000 abstract description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 abstract description 2
- 230000001717 pathogenic effect Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 abstract description 2
- 210000001835 viscera Anatomy 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 206010011224 Cough Diseases 0.000 description 10
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 8
- 206010036790 Productive cough Diseases 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 206010008479 Chest Pain Diseases 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 description 4
- 241000219061 Rheum Species 0.000 description 4
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000006996 mental state Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000026425 severe pneumonia Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 244000144725 Amygdalus communis Species 0.000 description 2
- 235000011437 Amygdalus communis Nutrition 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000972673 Phellodendron amurense Species 0.000 description 2
- 108010048233 Procalcitonin Proteins 0.000 description 2
- 241000207929 Scutellaria Species 0.000 description 2
- 108700028909 Serum Amyloid A Proteins 0.000 description 2
- 102000054727 Serum Amyloid A Human genes 0.000 description 2
- 240000001949 Taraxacum officinale Species 0.000 description 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 235000020224 almond Nutrition 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000036391 respiratory frequency Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000118350 Andrographis paniculata Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 240000004638 Dendrobium nobile Species 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 241000288140 Gruiformes Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000334154 Isatis tinctoria Species 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 241000801118 Lepidium Species 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 240000002948 Ophiopogon intermedius Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010037457 Pulmonary vasculitis Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 229960000796 barbital sodium Drugs 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000005337 ground glass Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008517 radix Trichosanthis Substances 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229940041008 second-generation cephalosporins Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229940041007 third-generation cephalosporins Drugs 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for treating community-acquired pneumonia, which is prepared from the following raw materials in parts by weight: 26-34 parts of radix cynanchi wilfordii, 5-13 parts of white mulberry root-bark, 4-8 parts of raw ephedra herb, 5-13 parts of bitter apricot seed and raw gypsum Decocting first 26-34 parts of radix bupleuri, 5-13 parts of radix scutellariae, 4-8 parts of raw rheum officinale and 5-13 parts of raw liquorice. The invention also provides application of the traditional Chinese medicine composition. The advantages are that: the invention adopts the treatment principles of purging lung, purging viscera, and clearing and resolving, takes ephedra as a monarch drug, and releases lung to purge pathogenic heat; gypsum Fibrosum, cortex Mori, radix et rhizoma Rhei and rhizoma Fagopyri Dibotryis are used as ministerial drugs for clearing lung heat without keeping evil, eliminating phlegm turbid, and descending lung qi; bupleurum root, baikal skullcap root and bitter apricot seed are used as adjuvant drugs to relieve diarrheaLiver fire, preventing liver counter-restriction and lung counter-restriction embody the idea of 'treating disease' in traditional Chinese medicine; glycyrrhrizae radix is used as a guiding drug for invigorating qi and regulating stomach and harmonizing various drugs.
Description
[ field of technology ]
The invention relates to a traditional Chinese medicine composition for treating community-acquired pneumonia and application thereof, in particular to a Chinese patent medicine prepared by taking Chinese herbal medicines as raw materials.
[ background Art ]
Community-acquired Pneumonia, CAP) is a type of pneumonia that is caused by infection of many microorganisms, such as bacteria, viruses, chlamydia and mycoplasma, outside the hospital, and the main clinical symptoms are cough, with or without expectoration and chest pain, and the prodromal symptoms are mainly rhinitis-like symptoms or symptoms of upper respiratory tract infection, such as nasal obstruction, nasal discharge, sneeze, dry throat, pharyngalgia, pharyngeal foreign body sensation, hoarseness, headache, dizziness, eye thermal distension, lacrimation, and mild cough. Community-acquired pneumonia is one of the common infectious diseases threatening human health, and the composition and drug resistance characteristics of its pathogens vary significantly from country to country and from region to region, and also change over time.
At present, western medicine mainly adopts second and third generation cephalosporins, beta lactams and fluoroquinolones for treatment, and has certain curative effect, but the phenomenon of drug resistance is serious along with the transition of pathogenic microorganisms, and side effects are large, and part of drugs are expensive, so that the traditional Chinese medicine composition is difficult to popularize generally.
The Chinese patent document CN200710131244.3 discloses a traditional Chinese medicine for treating pneumonia, which is prepared from the following raw materials in parts by weight: the main prescription is as follows: 30 g of gypsum, 5g of ephedra, 15 g of almond, 5g of liquorice, 30 g of houttuynia cordata, 24 g of scutellaria baicalensis, 30 g of dandelion, 30 g of polygonum cuspidatum, 30 g of andrographis paniculata and 15 g of dyers woad leaf; auxiliary prescription: for chest pain patients, 10g of radix Curcumae, rhizoma corydalis and radix aucklandiae are added respectively; for patients with severe asthma, 10g of mulberry bark and 15 g of pepperweed seed are added; for patients with oliguria with yellowish and reddish urine, 15 g of plantain herb and 10g of amur corktree bark are added; for those with excessive heat and body fluid impairment, 15 g of radix trichosanthis, 30 g of reed rhizome, 10g of dwarf lilyturf tuber and dendrobium nobile are added.
The traditional Chinese medicine has great advantages in improving symptoms and signs, shortening treatment course and improving overall treatment effect, and the traditional Chinese medicine composition for effectively treating community-acquired pneumonia is very necessary for the research.
[ invention ]
The invention aims at overcoming the defects in the prior art and provides a traditional Chinese medicine composition for treating community-acquired pneumonia.
It is a further object of the present invention to provide a use of the above medicament.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
a traditional Chinese medicine composition for treating community-acquired pneumonia is prepared from the following raw materials in parts by weight: 26-34 parts of radix cynanchi wilfordii, 5-13 parts of white mulberry root-bark, 4-8 parts of raw ephedra herb, 5-13 parts of bitter apricot seed and raw gypsum Decocting first 26-34 parts of radix bupleuri, 5-13 parts of radix scutellariae, 4-8 parts of raw rheum officinale and 5-13 parts of raw liquorice;
preferably, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 28-32 parts of radix cynanchi wilfordii, 7-11 parts of white mulberry root-bark, 5-7 parts of raw ephedra herb, 7-11 parts of bitter apricot seed and raw gypsum Decocting first 28-32 parts of radix bupleuri, 7-11 parts of radix scutellariae, 5-7 parts of raw rheum officinale and 7-11 parts of raw liquorice;
more preferably, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 30 parts of radix cynanchi wilfordii, 9 parts of white mulberry root-bark, 6 parts of raw ephedra herb, 9 parts of bitter apricot seed and plaster stone Decocting first 30 parts of bupleurum, 9 parts of scutellaria baicalensis, 6 parts of raw rheum officinale and 9 parts of raw liquorice.
Preferably, the use method of the traditional Chinese medicine composition comprises the following steps: soaking all the medicinal materials in purified water for 0.5-1.5 hours, controlling the water adding amount to be 2-3 cm higher than the surface of the medicinal materials, boiling with strong fire, decocting with slow fire for half an hour, removing residues and taking the juice; the filter residue is processed again by the method, and then 400ml of water decoction obtained by mixing the two times is taken orally, 2 times a day, 200ml each time.
Preferably, the medicament of the traditional Chinese medicine composition is decoction, tablets, capsules, granules, oral liquid, mixture or syrup.
In order to achieve the second purpose, the invention adopts the following technical scheme:
the application of the traditional Chinese medicine composition in preparing medicines for preventing/treating community-acquired pneumonia.
The invention has the advantages that:
the invention adopts the treatment principles of purging lung, purging viscera, and clearing and resolving, takes ephedra as a monarch drug, and releases lung to purge pathogenic heat; gypsum Fibrosum, cortex Mori, radix et rhizoma Rhei and rhizoma Fagopyri Dibotryis are used as ministerial drugs for clearing lung heat without keeping evil, eliminating phlegm turbid, and descending lung qi; bupleurum, scutellaria baicalensis and bitter apricot seed are used as adjuvant drugs to dispel liver fire and prevent liver counter-restriction of lung, thus embodying the idea of 'treating disease' in traditional Chinese medicine; glycyrrhrizae radix is used as a guiding drug for invigorating qi and regulating stomach and harmonizing various drugs.
[ detailed description ] of the invention
The following provides a detailed description of specific embodiments of the invention.
Example 1 Chinese medicinal composition for treating community-acquired pneumonia (I)
30 parts of radix cynanchi wilfordii, 9 parts of white mulberry root-bark, 6 parts of raw ephedra herb, 9 parts of bitter apricot seed and plaster stone Decocting first 30 parts of bupleurum, 9 parts of scutellaria baicalensis, 6 parts of raw rheum officinale and 9 parts of raw liquorice.
Example 2 Chinese medicinal composition for treating community-acquired pneumonia (II)
30 parts of radix cynanchi wilfordii, 7 parts of white mulberry root-bark, 7 parts of raw ephedra herb, 5 parts of bitter apricot seed and gypsum Decocting first 34 parts of bupleurum, 7 parts of baical skullcap root, 7 parts of raw rhubarb and 5 parts of raw liquoric root.
Example 3 Chinese medicinal composition for treating community-acquired pneumonia (III)
28 parts of radix cynanchi wilfordii, 11 parts of white mulberry root-bark, 4 parts of raw ephedra herb, 13 parts of bitter apricot seed and plaster stone Decocting first 30 parts of bupleurum, 7 parts of radix scutellariae, 11 parts of raw rheum officinale, 4 parts of raw liquorice and 13 parts of raw liquorice.
Example 4 Chinese medicinal composition for treating community-acquired pneumonia (IV)
32 parts of radix cynanchi wilfordii, 5 parts of white mulberry root-bark, 8 parts of raw ephedra herb, 9 parts of bitter apricot seed and plaster stone Decocting first 28 parts of radix bupleuri, 11 parts of radix scutellariae, 5 parts of raw rheum officinale, 8 parts of raw liquorice and 9 parts of raw liquorice.
Example 5 Chinese medicinal composition for treating community-acquired pneumonia (five)
26 parts of radix cynanchi wilfordii, 13 parts of white mulberry root-bark, 6 parts of raw ephedra herb, 7 parts of bitter apricot seed and plaster stone Decocting first 32 parts of radix bupleuri, 5 parts of radix scutellariae, 13 parts of raw rheum officinale, 6 parts of raw liquorice and 7 parts of raw liquorice.
Example 6 Chinese medicinal composition for treating community-acquired pneumonia (six)
34 parts of radix cynanchi wilfordii, 9 parts of white mulberry root-bark, 5 parts of raw ephedra herb, 11 parts of bitter apricot seed and plaster stone Decocting first 26 parts of radix bupleuri, 13 parts of radix scutellariae, 9 parts of raw rheum officinale, 5 parts of raw liquorice and 11 parts of raw liquorice.
Example 7 Chinese medicinal composition for treating community-acquired pneumonia (seven)
30 parts of radix cynanchi wilfordii, 11 parts of white mulberry root-bark, 4 parts of raw ephedra herb, 13 parts of bitter apricot seed and plaster stone Decocting first 30 parts of bupleurum, 7 parts of radix scutellariae, 11 parts of raw rheum officinale, 4 parts of raw liquorice and 13 parts of raw liquorice.
Example 8 Chinese medicinal composition for treating community-acquired pneumonia (eight)
28 parts of radix cynanchi wilfordii, 5 parts of white mulberry root-bark, 8 parts of raw ephedra herb, 9 parts of bitter apricot seed and plaster stone Decocting first 28 parts of radix bupleuri, 11 parts of radix scutellariae, 5 parts of raw rheum officinale, 8 parts of raw liquorice and 9 parts of raw liquorice.
Example 9 Chinese medicinal composition for treating community-acquired pneumonia (nine)
32 parts of radix cynanchi wilfordii, 13 parts of white mulberry root-bark, 6 parts of raw ephedra herb, 7 parts of bitter apricot seed and plaster stone Decocting first 32 parts of radix bupleuri, 5 parts of radix scutellariae, 13 parts of raw rheum officinale, 6 parts of raw liquorice and 7 parts of raw liquorice.
Example 10 Chinese medicinal composition for treating community-acquired pneumonia (ten)
26 parts of radix cynanchi wilfordii, 9 parts of white mulberry root-bark, 5 parts of raw ephedra herb, 11 parts of bitter apricot seed and plaster stone Decocting first 26 parts of radix bupleuri, 13 parts of radix scutellariae, 9 parts of raw rheum officinale, 5 parts of raw liquorice and 11 parts of raw liquorice.
Example 11 Chinese medicinal composition for the treatment of community-acquired pneumonia (eleven)
34 parts of radix cynanchi wilfordii, 7 parts of white mulberry root-bark, 7 parts of raw ephedra herb, 5 parts of bitter apricot seed and raw gypsum Decocting first 34 parts of bupleurum, 7 parts of baical skullcap root, 7 parts of raw rhubarb and 5 parts of raw liquoric root.
EXAMPLE 12 preparation of Chinese medicinal composition tablet/Capsule for treating community-acquired pneumonia
Taking the traditional Chinese medicine composition in any one of embodiments 1-11, adding 9-11 times of water, decocting for 2-3.5 hours, and filtering out the decoction. Adding 9 times of water, decocting for 2.5 hr, filtering to obtain decoction, mixing the two decoctions, standing, filtering to obtain supernatant, concentrating, cooling, adding 3 times of ethanol, and stirring to precipitate overnight. Collecting supernatant, concentrating to obtain soft extract; adding pharmaceutical adjuvants, vacuum drying, pulverizing, granulating, and making into tablet or capsule.
EXAMPLE 13 preparation of Chinese medicinal composition particles for treating community-acquired pneumonia
Taking the traditional Chinese medicine composition in any one of embodiments 1-11, adding 8-10 times of water, decocting for 3 hours, and filtering out the decoction. Adding 10 times of water, decocting for 2.5 hr, filtering to obtain decoction, mixing the two decoctions, standing, filtering to obtain supernatant, concentrating, cooling, adding 2 times of ethanol, and stirring to precipitate overnight. Collecting supernatant, concentrating to obtain soft extract; adding proper pharmaceutical adjuvants, granulating, drying, grading to obtain 20g granule, and packaging into 10 g/bag.
EXAMPLE 14 preparation of Chinese medicinal composition mixture/oral liquid/syrup for treating community-acquired pneumonia
Taking the traditional Chinese medicine composition in any one of embodiments 1-11, adding 8-11 times of water, decocting for 3 hours, and filtering out the decoction. Adding 8 times of water, decocting for 3 hr, filtering to obtain decoction, mixing the two decoctions, standing, filtering to obtain supernatant, concentrating, cooling, adding 3.5 times of ethanol, and stirring to precipitate overnight. Collecting supernatant, concentrating to obtain soft extract; adding proper pharmaceutical adjuvants, and making into mixture, oral liquid or syrup.
Example 15 animal experiment
1. Experimental materials
1.1 drugs and Agents
Treatment group one preparation: 30 parts of radix cynanchi wilfordii, 9 parts of white mulberry root-bark, 6 parts of raw ephedra herb, 9 parts of bitter apricot seed and plaster stone Decocting first 30 parts of bupleurum, 9 parts of scutellaria baicalensis, 6 parts of raw rheum officinale and 9 parts of raw liquorice;
treatment group two preparation: 28 parts of radix cynanchi wilfordii, 11 parts of white mulberry root-bark, 4 parts of raw ephedra herb and bitter taste13 parts of almond and gypsum Decocting first 30 parts of bupleurum, 7 parts of radix bupleuri, 11 parts of radix scutellariae, 4 parts of raw rheum officinale and 13 parts of raw liquorice;
control group one preparation: 30 parts of radix polygoni multiflori, 9 parts of pericarpium arecae, 6 parts of raw ephedra, 9 parts of bitter apricot seed and gypsum Decocting first 30 parts of kudzuvine root 9 parts, phellodendron bark 9 parts, raw rhubarb 6 parts and raw liquorice 9 parts;
control group two preparation: 28 parts of dandelion, 11 parts of white mulberry root-bark, 4 parts of raw ephedra herb, 13 parts of bitter apricot seed and gypsum Decocting first 30 parts of bupleurum root, 7 parts of ash bark, 11 parts of raw rhubarb, 4 parts of raw liquorice and 13 parts of raw liquorice;
blank group: physiological saline;
model group: physiological saline.
1.2 animals
60 mice, male and female halves, weighing 20+ -5 g, were purchased from Shanghai Sipulel-BiKai laboratory animal Co.
1.3 major reagents and instruments
An LPS solution; TNF-alpha kit, IL-1 beta kit and IL-6 kit are all products of RB company in the United states.
2. Method and results
2.1 grouping
The 60 mice were grouped into model, treatment two, control one, control two, and blank.
2.2 moulding and administration
Nose drops of LPS (10 mg/kg body weight) are adopted for molding, and water is not forbidden after 12 hours of fasted before molding. Injecting 3% barbital sodium solution into the abdominal cavity of a mouse for anesthesia, accurately sucking LPS solution with the concentration of 10mg/mL by using a pipettor, controlling the head of the mouse by a left hand, slightly pushing the liquid device by a right hand, enabling the gun head to see sucked small liquid drops, slightly leaning against the right nostril of the mouse, immediately and forcefully lifting up by about 30cm by the left hand, slowly and slightly returning to the left hand starting position, carrying out back and forth 10 times, then dripping the small liquid drops into the left nostril of the mouse by the same operation, sequentially dripping the left nostril and the right nostril until liquid instillation is completed, finally loosening the mouse, placing the mouse on a mouse plate, keeping the body position with the abdomen upwards and the head upwards for more than 30min, and placing the mouse back to the original cage for feeding observation for resuscitation. After the molding, each group was administered with 0.1mL/10g (corresponding to 1.2mg/10g crude drug amount) of the extract of the corresponding drug, 1 time/day, and 14 days. Normal control and model groups were given equal amounts of physiological saline. Whole blood was collected from each group of mice at 15d for serum inflammatory factor determination.
2.3 detection index
(1) Observing the mental state and the activity state of each group of mice;
(2) The levels of TNF- α, IL-1β, and IL-6 in the serum of each group of mice were determined.
2.4 statistical methods
Data were statistically processed using SPSS25.0 software. The measurement data is expressed by (x+ -s), and the t-test is applied to the normal distributor.
2.5 results
2.5.1 comparison of mental State and Activity State of mice of groups
Mice in the treatment group and the control group are normal in performance, smooth in hair, relatively active, uniform in breathing and sensitive in response; model group mice have poor mental state, slow response, disordered hair, a bundle of wound, auscultation and lung roar finding, etc. Compared with the model group, the different administration groups have better overall condition, and especially mice in the treatment group have more frequent movements and more sensitive response.
2.5.2 comparison of TNF-alpha, IL-1 beta and IL-6 levels in serum from mice of groups
Mouse blood samples were taken and assayed for TNF- α, IL-1β, and IL-6 levels in serum by performing the procedure described in ELISA kit. The levels of TNF- α, IL-1β and IL-6 were significantly increased in the serum of mice in the model group compared to the blank group (p < 0.01); the levels of TNF-alpha, IL-1 beta and IL-6 in the serum of mice in the treatment group, control group were significantly reduced compared to the model group (p <0.01, p < 0.05); the serum levels of TNF- α, IL-1β and IL-6 were reduced in the treated mice compared to the control group (p < 0.05), and there was no significant difference in IL-6 in the treated mice compared to the control group, and the results are shown in Table 1.
TABLE 1 comparison of TNF-alpha, IL-1 beta and IL-6 content in serum of mice of each group
Note that: 1) compared with blank group, p<0.01； 2) Compared with the model group, (p)<0.01、p<0.05)； 3) Compared with the control group, (p)<0.05)。
Example 16 clinical trials
1. Data and method
1.1 clinical data
The study cases were obtained from pneumology community-acquired pneumonic phlegm-heat-accumulation lung type patients in the period of 1 month-2021 month in 2020, and 180 cases were randomly divided into 90 treatment groups and 90 control groups.
1.2 diagnostic criteria
1.2.1 Western diagnostic criteria: reference is made to the guidelines for diagnosis and treatment of acquired pneumonia in the chinese adult community (2016 edition):
(1) Community morbidity;
(2) Pneumonia-related clinical manifestations: (1) cough, expectoration or exacerbation of the symptoms of the original respiratory disease are newly developed with or without purulent sputum/chest pain/dyspnea/hemoptysis. (2) Heating. (3) Syndrome of lung-excess type and/or smelling and wetting the rales. (4) Peripheral blood White Blood Cells (WBC) > 10×10 9 individual/L or < 4×10 9 Left shift of cell nucleus with or without cell/L;
(3) Chest imaging showed new appearance of patchy infiltrates, leaf/segment solid lesions, ground glass shadows or interstitial changes with or without pleural effusions.
The clinical diagnosis can be established after meeting any 1 in (1), (2) and (3) and excluding tuberculosis, lung tumor, noninfectious pulmonary interstitial disease, pulmonary edema, pulmonary atelectasis, pulmonary embolism, eosinophilic infiltration, pulmonary vasculitis and the like.
1.2.2 diagnostic criteria for severe pneumonia (severepneumia)
Severe pneumonia can be diagnosed if CAP meets the following 1 primary standard or ≡3 secondary standards.
The main standard is as follows: (1) mechanical ventilation treatment of the trachea cannula is needed; (2) vascular active drug therapy is still required after septic shock is resuscitated by aggressive fluid.
Secondary standard: (1) the respiratory frequency is more than or equal to 30 times/minute; (2) pa02/Fi02 is less than or equal to 250mmHg (1 mmHg=0.133 kPa); (3) infiltration of multiple lung lobes; (4) a disturbance of consciousness and/or a disturbance of orientation; (5) blood urea nitrogen is more than or equal to 20mg/dl (7.14 mmol/L); (6) systolic pressure < 90mmHg, active fluid resuscitation is required.
CURB-65 is recommended as a criterion for determining whether a CAP patient needs hospitalization. CURB-65 total five indexes, satisfying 1 to obtain 1 score: (1) a disturbance of consciousness; (2) urea nitrogen > 7mmol/L; (3) the respiratory frequency is more than or equal to 30 times/minute; (4) systolic pressure is less than 90mmHg or diastolic pressure is less than or equal to 60mmHg; (5) the age is more than or equal to 65 years old. Scoring 0-1 score, in principle outpatient treatment; hospitalization or off-hospital treatment under strict follow-up is recommended 2 points; hospitalization should be performed for 3-5 minutes. Meanwhile, the comprehensive judgment of the age, basic diseases, social and economic conditions, gastrointestinal functions, treatment compliance and the like of the patient should be combined.
1.2.3 diagnostic criteria for chinese medicine: determining phlegm-heat obstructing lung type CAP diagnosis standard according to the Community acquired pneumonia traditional Chinese medicine diagnosis and treatment guide (2018 revision), specifically comprising the following steps:
the traditional Chinese medicine syndrome waiting diagnosis: wind-warm lung-heat disease-syndrome of phlegm-heat obstructing the lung.
Main symptoms are as follows: cough, excessive phlegm, yellow phlegm, dry and sticky phlegm and chest pain.
Secondary symptoms: fever, thirst, flushed face, yellow urine, dry stool and abdominal distention.
Tongue pulse: a red tongue with yellow and greasy coating and a slippery and rapid pulse.
Diagnosis: (1) cough and even chest pain; (2) yellow or white dry sticky sputum; (3) fever, thirst; (4) dry stool or abdominal distension; (5) the tongue is reddish, yellow or yellow and greasy coating, and the pulse is rapid or slippery and rapid. The method comprises 2 items (1) and (2), and 2 items (3), (4) and (5).
1.3 inclusion criteria
(1) Meets the CAP Western diagnosis standard;
(2) Meets the traditional Chinese medicine diagnosis standard of phlegm-heat obstructing lung;
(3) Age 18-85 years;
(4) Those who have not used antibiotic drugs within 72 hours after the current illness;
(5) The patient voluntarily participates and signs informed consent.
1.4 methods of treatment
Control group: the basic treatment of CAP guidelines is given to resist infection, relieve fever, eliminate phlegm and relieve airway spasm;
treatment group: based on basic treatment, the pneumonia clearing mixture is orally taken. Observing the symptoms such as body temperature, cough, expectoration and the like before and after the treatment of patients and the change of inflammatory indexes.
1.5 evaluation of therapeutic Effect
1.5.1 therapeutic Effect Observation index
The main curative effect index is as follows: baseline and treatment for 7 days.
Secondary efficacy index:
(1) Peripheral blood WBC, percent neutrophil (NEUT%), C-reactive protein (CRP), serum Amyloid A (SAA), procalcitonin (PCT) changes: record before treatment and day 7 of treatment;
(2) Chest CT: recording lung image change before and on day 7 of treatment;
(3) Detecting novel coronavirus nucleic acid by real-time fluorescent RT-PCR (once before and after treatment) of samples such as sputum, throat swab, lower respiratory tract secretion and the like;
(4) Baseline and 7 days of disease combined outcome (severe pneumonia conversion, pneumonia outcome index, etc.);
(5) Average number of hospitalization days, total hospitalization cost, etc.
1.5.2 therapeutic efficacy criterion
And (3) formulating curative effect judgment standards according to the guidelines of clinical research on new traditional Chinese medicines.
(1) The comprehensive curative effect of the disease is that (1) the respiratory tract symptoms and the lung signs disappear, the fever is no longer generated, and the related physicochemical indexes are recovered to cure; (2) the respiratory tract symptoms and the lung physical signs are obviously improved, no fever is generated any more, and the related physicochemical index level is obviously optimized to be obvious; (3) the improvement comprises the effective improvement of respiratory symptoms and pulmonary signs, the gradual recovery of the body temperature, and the recovery of relevant physicochemical indexes; (4) invalidation: no change in respiratory symptoms or pulmonary signs was ineffective.
Total effective rate = cure rate + apparent efficiency.
(2) The nimodipine method is adopted to evaluate the curative effect of the traditional Chinese medicine symptoms: efficacy index = difference between post-treatment and pre-treatment scores/pre-treatment score x 100%. The curative effect indexes of cure, obvious effect, effective and ineffective are respectively more than or equal to 95%, 70% -95% (excluding 95%), 30% -70% (excluding 70%) and less than 30%.
2. Results
2.1 evaluation of efficacy
The total effective rate of the treated group is obviously improved (96.7 percent, 58/60) after treatment, which is obviously higher than that of the control group (85.0 percent, 51/60), and the difference between the two groups has statistical significance (p < 0.05).
Table 3 comparison of total efficacy for two groups of patients [ example (%)
Note that: p <0.05 compared to the control group.
2.2 comparison of fever time
The treatment group had significantly shorter duration of heat than the control group (p < 0.05).
Table 4 comparative antipyretic time of two groups of patients
Note that: p <0.05 compared to the control group.
2.3 cough disappearance time comparison
The cough disappearance time was significantly improved in the treated group compared to the control group (p < 0.05).
Table 5 comparison of cough disappearance times in two groups of patients
Note that: p <0.05 compared to the control group.
3. Conclusion(s)
The pneumonia clear compound agent has obvious anti-inflammatory effect, shortens the fever and cough relieving time of patients with community-acquired pneumonia phlegm-heat syndrome, has obvious curative effect on relieving symptoms such as expectoration, thirst, constipation and the like, can accelerate and reduce inflammatory reaction, improves treatment effect, and has good safety.
The foregoing is merely a preferred embodiment of the present invention, and it should be noted that modifications and additions may be made to those skilled in the art without departing from the method of the present invention, which modifications and additions are also to be considered as within the scope of the present invention.
Claims (6)
1. The traditional Chinese medicine composition for treating community-acquired pneumonia is characterized by being prepared from the following raw materials in parts by weight: 26-34 parts of radix cynanchi wilfordii, 5-13 parts of white mulberry root-bark, 4-8 parts of raw ephedra herb, 5-13 parts of bitter apricot seed and raw gypsum Decocting first 26-34 parts of radix bupleuri, 5-13 parts of radix scutellariae, 4-8 parts of raw rheum officinale and 5-13 parts of raw liquorice.
2. The traditional Chinese medicine composition according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight: 28-32 parts of radix cynanchi wilfordii, 7-11 parts of white mulberry root-bark, 5-7 parts of raw ephedra herb, 7-11 parts of bitter apricot seed and raw gypsum Decocting first 28-32 parts of radix bupleuri, 7-11 parts of radix scutellariae, 7-11 parts of raw rheum officinale, 5-7 parts of raw liquorice and 7-11 parts of raw liquorice.
3. The traditional Chinese medicine composition according to claim 2, which is characterized by being prepared from the following raw materials in parts by weight: 30 parts of radix cynanchi wilfordii, 9 parts of white mulberry root-bark, 6 parts of raw ephedra herb, 9 parts of bitter apricot seed and plaster stone Decocting first 30 parts of bupleurum, 9 parts of scutellaria baicalensis, 6 parts of raw rheum officinale and 9 parts of raw liquorice.
4. The traditional Chinese medicine composition according to any one of claims 1-3, wherein the use method of the traditional Chinese medicine composition is as follows: soaking all the medicinal materials in purified water for 0.5-1.5 hours, controlling the water adding amount to be 2-3 cm higher than the surface of the medicinal materials, boiling with strong fire, decocting with slow fire for half an hour, removing residues and taking the juice; the filter residue is processed again by the method, and then 400ml of water decoction obtained by mixing the two times is taken orally, 2 times a day, 200ml each time.
5. The Chinese medicinal composition according to any one of claims 1 to 3, wherein the medicament of the Chinese medicinal composition is a decoction, a tablet, a capsule, a granule, an oral liquid, a mixture or a syrup.
6. Use of the Chinese medicinal composition according to any one of claims 1-3 in the preparation of a medicament for the prevention/treatment of community-acquired pneumonia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310415233.7A CN117257866B (en) | 2023-04-18 | 2023-04-18 | Traditional Chinese medicine composition for treating community-acquired pneumonia and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310415233.7A CN117257866B (en) | 2023-04-18 | 2023-04-18 | Traditional Chinese medicine composition for treating community-acquired pneumonia and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117257866A true CN117257866A (en) | 2023-12-22 |
| CN117257866B CN117257866B (en) | 2024-06-18 |
Family
ID=89213071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310415233.7A Active CN117257866B (en) | 2023-04-18 | 2023-04-18 | Traditional Chinese medicine composition for treating community-acquired pneumonia and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117257866B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104666495A (en) * | 2015-03-27 | 2015-06-03 | 刘庆斌 | Chinese medicinal composition for treating lobar pneumonia and application of combined point acupuncture |
| CN110946922A (en) * | 2019-12-27 | 2020-04-03 | 上海中医药大学附属曙光医院 | Traditional Chinese medicine composition for treating pulmonary fibrosis and application thereof |
| CN115282221A (en) * | 2022-07-26 | 2022-11-04 | 上海中医药大学附属曙光医院 | Traditional Chinese medicine composition for treating idiopathic pulmonary fibrosis and application thereof |
| CN116459295A (en) * | 2023-04-18 | 2023-07-21 | 上海中医药大学 | Pneumonia clearing prescription and application thereof |
-
2023
- 2023-04-18 CN CN202310415233.7A patent/CN117257866B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104666495A (en) * | 2015-03-27 | 2015-06-03 | 刘庆斌 | Chinese medicinal composition for treating lobar pneumonia and application of combined point acupuncture |
| CN110946922A (en) * | 2019-12-27 | 2020-04-03 | 上海中医药大学附属曙光医院 | Traditional Chinese medicine composition for treating pulmonary fibrosis and application thereof |
| CN115282221A (en) * | 2022-07-26 | 2022-11-04 | 上海中医药大学附属曙光医院 | Traditional Chinese medicine composition for treating idiopathic pulmonary fibrosis and application thereof |
| CN116459295A (en) * | 2023-04-18 | 2023-07-21 | 上海中医药大学 | Pneumonia clearing prescription and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| ZHANG H, ET AL: "Fei-Yan-Qing-Hua decoction decreases hyperinflammation by inhibiting HMGB1/RAGE signaling and promotes bacterial phagocytosis in the treatment of sepsis", JOURNAL OF ETHNOPHARMACOLOGY, vol. 321, 6 December 2023 (2023-12-06), pages 1 - 16 * |
| 史苗颜，等: "六神丸联合基础治疗对支气管扩张症急性加重期风热犯肺证患者的临床疗效", 中成药, vol. 42, no. 08, 20 August 2020 (2020-08-20), pages 2243 - 2245 * |
| 王力宁，等: "中医药治疗小儿肺炎喘嗽风热闭肺证、痰热闭肺证临床验证方案的多中心随机对照研究", 中国中西医结合儿科学, vol. 02, no. 05, 25 October 2010 (2010-10-25), pages 386 - 391 * |
| 郭华明: "中西医结合治疗小儿肺炎86例疗效观察", 新中医, no. 07, 15 July 2006 (2006-07-15), pages 61 - 62 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117257866B (en) | 2024-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2450047B1 (en) | Pharmaceutical composition containing ephedrae for treating bronchitis and preparation method therefor | |
| CN112353855A (en) | Application of traditional Chinese medicine composition in preparation of medicine for adjuvant therapy of novel coronavirus pneumonia | |
| CN111388582B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application of preparation thereof | |
| CN112316032A (en) | Application of traditional Chinese medicine composition in preparation of novel coronavirus resistant medicines | |
| CN116139237B (en) | A Chinese medicinal composition for preventing and treating respiratory tract infection caused by coronavirus, and its application | |
| CN115400194B (en) | Traditional Chinese medicine composition for treating children epidemic and application thereof | |
| CN117257866B (en) | Traditional Chinese medicine composition for treating community-acquired pneumonia and application thereof | |
| CN115381915B (en) | Traditional Chinese medicine composition for treating phlegm-heat stasis type pulmonary nodules, and preparation method and application thereof | |
| CN113995821B (en) | Chinese medicinal composition for treating pneumonia caused by novel coronavirus and other viruses, preparation and preparation method thereof | |
| CN113368198B (en) | Pharmaceutical composition for treating wind-heat affecting lung and preparation method and application thereof | |
| CN102397458B (en) | Medicinal composition for treating senile pneumonia and preparation method thereof | |
| WO2021179881A1 (en) | Application of herbal medicine composition in preparation of medicine for preventing and treating coronavirus complicated with lung injury | |
| CN111228367B (en) | Traditional Chinese medicine external lotion for treating infantile anaphylactoid purpura and preparation method thereof | |
| CN111388551A (en) | Traditional Chinese medicine composition for reducing fat, discharging turbidity and clearing intestines, application and preparation method thereof | |
| CN111588757A (en) | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in stable phase and preparation method thereof | |
| CN108355124A (en) | A kind of Chinese medicine composition that treating Air way mucus hypersecretion and its application | |
| CN104096053A (en) | Medicine composition for treating infantile pneumonia | |
| CN112138105B (en) | Traditional Chinese medicine composition for treating bronchiectasis lung-spleen qi deficiency and phlegm-damp lung blocking syndrome and application thereof | |
| CN107050340B (en) | Traditional Chinese medicine composition for treating necrotizing lymphadenitis and application thereof | |
| CN116036202B (en) | Traditional Chinese medicine composition for clearing heat and detoxicating, and preparation method and application thereof | |
| CN107184651B (en) | Traditional Chinese medicine composition for clearing away heat and toxic materials and preparation method and application thereof | |
| CN111375036B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof | |
| CN102233026B (en) | Pharmaceutical composition and preparation method and application thereof | |
| CN107510753B (en) | Traditional Chinese medicine composition for treating intractable hemoptysis and application thereof | |
| CN118267445A (en) | Traditional Chinese medicine composition for treating severe pneumonia and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |